€13m brings glimin of hope for Poxel in type 2 diabetes
This article was originally published in Scrip
Executive Summary
Poxel, a Merck Serono spin-off company based in France, will use €13 million raised in a series B financing round to prepare its novel first-in-class oral anti-diabetic, imeglimin, for Phase III studies.